echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > This Guangdong pharmaceutical company has reviewed a large variety of 6 billion injections

    This Guangdong pharmaceutical company has reviewed a large variety of 6 billion injections

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      Medical Network News, April 25, April 23, NMPA official website showed that Guangdong Jincheng Jinsu Pharmaceutical's ceftazidime for injection passed the consistency evaluation.
    Ceftazidime for injection is the fifth batch of varieties to be collected.
    According to data from Minai.
    com, terminal ceftazidime sales in China's public medical institutions exceeded 6 billion yuan in 2019.
     
      Ceftazidime belongs to the third-generation semi-synthetic cephalosporins.
    It has the characteristics of broad antibacterial spectrum and enzyme resistance.
    It is suitable for the treatment of single or multiple infections caused by sensitive microorganisms, such as systemic severe infections, lower respiratory tract infections, ear, nose, and throat infections, and urine.
    Road infection and so on.
    Ceftazidime is in the 2018 National Essential Drug List and the 2020 National Essential Medical Insurance List, and the original manufacturer is GlaxoSmithKline.
     
      According to Meinenet data, in 2019, the sales of ceftazidime for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 6 billion yuan, and its sales in 2020H1 were close to 2.
    5 billion yuan.
    , Hainan Hailing Chemical Pharmaceuticals occupies more than 50% of the market share.
     
      Terminal Ceftazidime Sales in Public Medical Institutions in China
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      Ceftazidime for injection is the fifth batch of varieties to be collected.
    Meters within the network database consistency evaluation, the current evaluation ceftazidime for injection through
    enterprises has seven, including Qilu Pharmaceutical, Pharmaceutical special times, Yangtze River Pharmaceutical, Korea and the US Pharmaceutical, Hailing Pharmaceutical, Kim So-and Hainan Jincheng Swiss co Pharmaceutical.
     
      Up to now, Jincheng Jinsu has passed the consistency evaluation of 3 injections, including Cefazolin Sodium for Injection, Ceftriaxone Sodium for Injection and Ceftazidime for Injection, all of which are the fifth batch of varieties to be collected.
     
      Source: Mi Neiwang database, NMPA
      Medical Network News, April 25, April 23, NMPA official website showed that Guangdong Jincheng Jinsu Pharmaceutical's ceftazidime for injection passed the consistency evaluation.
    Ceftazidime for injection is the fifth batch of varieties to be collected.
    According to data from Minai.
    com, terminal ceftazidime sales in China's public medical institutions exceeded 6 billion yuan in 2019.
     
      Ceftazidime belongs to the third-generation semi-synthetic cephalosporins.
    It has the characteristics of broad antibacterial spectrum and enzyme resistance.
    It is suitable for the treatment of single or multiple infections caused by sensitive microorganisms, such as systemic severe infections, lower respiratory tract infections, ear, nose, and throat infections, and urine.
    Road infection and so on.
    Ceftazidime is in the 2018 National Essential Drug List and the 2020 National Essential Medical Insurance List, and the original manufacturer is GlaxoSmithKline.
     
      According to Meinenet data, in 2019, the sales of ceftazidime for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 6 billion yuan, and its sales in 2020H1 were close to 2.
    5 billion yuan.
    , Hainan Hailing Chemical Pharmaceuticals occupies more than 50% of the market share.
     
      Terminal Ceftazidime Sales in Public Medical Institutions in China
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      Ceftazidime for injection is the fifth batch of varieties to be collected.
    Meters within the network database consistency evaluation, the current evaluation ceftazidime for injection through
    enterprises has seven, including Qilu Pharmaceutical, Pharmaceutical special times, Yangtze River Pharmaceutical, Korea and the US Pharmaceutical, Hailing Pharmaceutical, Kim So-and Hainan Jincheng Swiss co Pharmaceutical.
     
      Up to now, Jincheng Jinsu has passed the consistency evaluation of 3 injections, including Cefazolin Sodium for Injection, Ceftriaxone Sodium for Injection and Ceftazidime for Injection, all of which are the fifth batch of varieties to be collected.
     
      Source: Mi Neiwang database, NMPA
      Medical Network News, April 25, April 23, NMPA official website showed that Guangdong Jincheng Jinsu Pharmaceutical's ceftazidime for injection passed the consistency evaluation.
    Ceftazidime for injection is the fifth batch of varieties to be collected.
    According to data from Minai.
    com, terminal ceftazidime sales in China's public medical institutions exceeded 6 billion yuan in 2019.
     
      Ceftazidime belongs to the third-generation semi-synthetic cephalosporins.
    It has the characteristics of broad antibacterial spectrum and enzyme resistance.
    It is suitable for the treatment of single or multiple infections caused by sensitive microorganisms, such as systemic severe infections, lower respiratory tract infections, ear, nose, and throat infections, and urine.
    Road infection and so on.
    Ceftazidime is in the 2018 National Essential Drug List and the 2020 National Essential Medical Insurance List, and the original manufacturer is GlaxoSmithKline.
     
      According to Meinenet data, in 2019, the sales of ceftazidime for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 6 billion yuan, and its sales in 2020H1 were close to 2.
    5 billion yuan.
    , Hainan Hailing Chemical Pharmaceuticals occupies more than 50% of the market share.
    Hospital hospital hospital
     
      Terminal Ceftazidime Sales in Public Medical Institutions in China
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      Ceftazidime for injection is the fifth batch of varieties to be collected.
    Meters within the network database consistency evaluation, the current evaluation ceftazidime for injection through
    enterprises has seven, including Qilu Pharmaceutical, Pharmaceutical special times, Yangtze River Pharmaceutical, Korea and the US Pharmaceutical, Hailing Pharmaceutical, Kim So-and Hainan Jincheng Swiss co Pharmaceutical.
    Enterprise business enterprise
     
      Up to now, Jincheng Jinsu has passed the consistency evaluation of 3 injections, including Cefazolin Sodium for Injection, Ceftriaxone Sodium for Injection and Ceftazidime for Injection, all of which are the fifth batch of varieties to be collected.
     
      Source: Mi Neiwang database, NMPA
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.